Results 171 to 180 of about 22,026 (263)

Effect of antidiabetic medication adherence on risk of all-cause mortality and cardiovascular diseases in type 2 diabetes patients: Impact of antidiabetic adherence on cardiovascular disease. [PDF]

Medicine (Baltimore)
Seo DH, Ha KH, Kim SH, Kim DJ.
europepmc   +1 more source

Case report: Epidermolysis bullosa acquisita following dipeptidyl peptidase-4 inhibitor therapy and complicated by immune thrombocytopenic purpura. [PDF]

Front Immunol
Kawamoto H, Sasaki N, Ueda Y, Ishii N, Sawada Y.   +4 more
europepmc   +1 more source

Repurposing dipeptidyl peptidase-4 inhibitor for Parkinson's disease prevention: A drug-target Mendelian randomization study. [PDF]

Neurotherapeutics
Lee JY, Park DG, Sung J.
europepmc   +1 more source

Dipeptidyl peptidase-4 inhibitors are associated with a lower risk of osteoarthritis in patients with type 2 diabetes. [PDF]

Ther Adv Musculoskelet Dis
Chen YH, Byers Kraus V, Chang YS, Lin TM, Lee HY, Chang CK, Kuo TT, Chen JH, Chang CC.   +8 more
europepmc   +1 more source

Prognostic Impact of DPP4 Inhibitors on Systemic Drug Therapy for Advanced Kidney Cancer Patients. [PDF]

Cancer Sci
Kamada S, Kitayama S, Yamase R, Ikeda K, Sato W, Sazuka T, Takeshita H, Sakamoto S, Yano A, Horie K, Ichikawa T, Kawakami S, Inoue S.   +12 more
europepmc   +1 more source

Cardiovascular and renal outcomes of sodium-glucose cotransporter-2 versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes post-PCI: a meta-analysis of 14,511 patients. [PDF]

Diabetol Metab Syndr
Badran AS, Gbreel MI, Tawfik AM, Balata M.   +3 more
europepmc   +1 more source

Clinical Outcomes with the Use of Dipeptidyl Peptidase-4 (DPP-4) Inhibitor Among Patients with Diabetes Mellitus and COVID-19: A Systematic Review of Observational Studies. [PDF]

J Clin Med
Alkhalifah SA, Alshahrani WA, Alshehri AM, Al Yami MS.   +3 more
europepmc   +1 more source

アログリプチンは非糖尿病被験者において食後高脂血症および食後血管内皮機能低下を改善する：予備報告 [PDF]

, 2015
Noda, Yoko
core  

Synthesis and pharmacological characterization of potent, selective, and orally bioavailable isoindoline class dipeptidyl peptidase IV inhibitors [PDF]

, 2011
Noriyasu Kato, Mitsuru Oka, Takayo Murase, Masahiro Yoshida, Masao Sakairi, Mirensha Yakufu, Satoko Yamashita, Yoshika Yasuda, Aya Yoshikawa, Yuji Hayashi, Masahiro Shirai, Yukie Mizuno, Mitsuaki Takeuchi, Mitsuhiro Makino, Motohiro Takeda, Takuji Kakigami   +15 more
core   +1 more source

Glucagon-Like Peptide 1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, and Risk of Autoimmune Rheumatic Diseases. [PDF]

Arthritis Rheumatol
Karacabeyli D, Lacaille D, Lu N, Xie H, Aviña-Zubieta JA.   +4 more
europepmc   +1 more source